biotech / news / / MarketScreener
Moderna's experimental influenza vaccine, Mflusiva, will be reviewed by experts.
The FDA will hold a public advisory committee meeting on Moderna's Mflusiva flu vaccine June 18.
KEY POINTS
- FDA initially rejected Moderna's Mflusiva application in February despite internal disagreements.
- Moderna's flu vaccine would be the first to use mRNA technology for influenza prevention.
- Health Secretary Robert F. Kennedy Jr. has publicly criticized mRNA-based vaccines like Moderna's.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →